Matching obinutuzumab dosing regimens for patients with DLBCL in Study GO29044 up to cycle 2 in patients with B-NHL in Study BO21003 allowed for a cross-study comparison of pola + G-CHP to single-agent obinutuzumab therapy based on cycle 2 pre-dose concentrations. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.